NCT06904222View on ClinicalTrials.gov

Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Respiratory Syncytial Virus Infection
Interventions
BIOLOGICAL

Low dose antigen of LYB005 without A01B adjuvant

0.5 mL per dose, containing a total of 30 μg antigen without A01B adjuvant.

BIOLOGICAL

Low dose antigen of LYB005 with A01B adjuvant

0.5 mL per dose, containing a total of 30 μg antigen adjuvanted with A01B.

BIOLOGICAL

Middle dose antigen of LYB005 without A01B adjuvant

0.5 mL per dose, containing a total of 60 μg antigen without A01B adjuvant.

BIOLOGICAL

Middle dose antigen of LYB005 with A01B adjuvant

0.5 mL per dose, containing a total of 60 μg antigen adjuvanted with A01B.

BIOLOGICAL

High dose antigen of LYB005 without A01B adjuvant

0.5 mL per dose, containing a total of 120 μg antigen without A01B adjuvant.

BIOLOGICAL

High dose antigen of LYB005 with A01B adjuvant

0.5 mL per dose, containing a total of 120 μg antigen adjuvanted with A01B.

BIOLOGICAL

Placebo

0.5 mL 0.9% sodium chloride (normal saline) injection per dose

Trial Locations (1)

Unknown

Dangyang City Center for Disease Control and Prevention, Dangyang

All Listed Sponsors
lead

Guangzhou Patronus Biotech Co., Ltd.

INDUSTRY